These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 37043904)
1. Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination. Stefanelli I; Corona A; Cerchia C; Cassese E; Improta S; Costanzi E; Pelliccia S; Morasso S; Esposito F; Paulis A; Scognamiglio S; Di Leva FS; Storici P; Brindisi M; Tramontano E; Cannalire R; Summa V Eur J Med Chem; 2023 May; 253():115311. PubMed ID: 37043904 [TBL] [Abstract][Full Text] [Related]
2. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV). Dampalla CS; Miller MJ; Kim Y; Zabiegala A; Nguyen HN; Madden TK; Thurman HA; Machen AJ; Cooper A; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC Eur J Med Chem; 2023 Jun; 254():115376. PubMed ID: 37080108 [TBL] [Abstract][Full Text] [Related]
3. Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL Kumar V; Shin JS; Shie JJ; Ku KB; Kim C; Go YY; Huang KF; Kim M; Liang PH Antiviral Res; 2017 May; 141():101-106. PubMed ID: 28216367 [TBL] [Abstract][Full Text] [Related]
4. The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate. Wang H; Pei R; Li X; Deng W; Xing S; Zhang Y; Zhang C; He S; Sun H; Xiao S; Xiong J; Zhang Y; Chen X; Wang Y; Guo Y; Zhang B; Shang L Eur J Med Chem; 2022 Aug; 238():114458. PubMed ID: 35635946 [TBL] [Abstract][Full Text] [Related]
5. Targeting zoonotic viruses: Structure-based inhibition of the 3C-like protease from bat coronavirus HKU4--The likely reservoir host to the human coronavirus that causes Middle East Respiratory Syndrome (MERS). St John SE; Tomar S; Stauffer SR; Mesecar AD Bioorg Med Chem; 2015 Sep; 23(17):6036-48. PubMed ID: 26190463 [TBL] [Abstract][Full Text] [Related]
6. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS. Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715 [TBL] [Abstract][Full Text] [Related]
7. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease. Akaji K; Konno H Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349 [TBL] [Abstract][Full Text] [Related]
8. Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and Bai B; Belovodskiy A; Hena M; Kandadai AS; Joyce MA; Saffran HA; Shields JA; Khan MB; Arutyunova E; Lu J; Bajwa SK; Hockman D; Fischer C; Lamer T; Vuong W; van Belkum MJ; Gu Z; Lin F; Du Y; Xu J; Rahim M; Young HS; Vederas JC; Tyrrell DL; Lemieux MJ; Nieman JA J Med Chem; 2022 Feb; 65(4):2905-2925. PubMed ID: 34242027 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of novel peptidomimetic inhibitors of the coronavirus 3C-like protease. Amblard F; LeCher JC; De R; Zhou S; Liu P; Goh SL; Tao S; Patel D; Downs-Bowen J; Zandi K; Zhang H; Chaudhry G; McBrayer T; Muczynski M; Al-Homoudi A; Engel J; Lan S; Sarafianos SG; Kovari LC; Schinazi RF Eur J Med Chem; 2024 Mar; 268():116263. PubMed ID: 38432056 [TBL] [Abstract][Full Text] [Related]
10. Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease. Dampalla CS; Rathnayake AD; Galasiti Kankanamalage AC; Kim Y; Perera KD; Nguyen HN; Miller MJ; Madden TK; Picard HR; Thurman HA; Kashipathy MM; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC J Med Chem; 2022 Jun; 65(11):7818-7832. PubMed ID: 35638577 [TBL] [Abstract][Full Text] [Related]
11. Exploration of the P1 residue in 3CL protease inhibitors leading to the discovery of a 2-tetrahydrofuran P1 replacement. Barton LS; Callahan JF; Cantizani J; Concha NO; Cotillo Torrejon I; Goodwin NC; Joshi-Pangu A; Kiesow TJ; McAtee JJ; Mellinger M; Nixon CJ; Padrón-Barthe L; Patterson JR; Pearson ND; Pouliot JJ; Rendina AR; Buitrago Santanilla A; Schneck JL; Sanz O; Thalji RK; Ward P; Williams SP; King BW Bioorg Med Chem; 2024 Feb; 100():117618. PubMed ID: 38309201 [TBL] [Abstract][Full Text] [Related]
12. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease. Xiong M; Nie T; Shao Q; Li M; Su H; Xu Y Eur J Med Chem; 2022 Mar; 231():114130. PubMed ID: 35114541 [TBL] [Abstract][Full Text] [Related]
13. A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals. Ma Y; Yang KS; Geng ZZ; Alugubelli YR; Shaabani N; Vatansever EC; Ma XR; Cho CC; Khatua K; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR Eur J Med Chem; 2022 Oct; 240():114570. PubMed ID: 35779291 [TBL] [Abstract][Full Text] [Related]
14. Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors. Bai B; Arutyunova E; Khan MB; Lu J; Joyce MA; Saffran HA; Shields JA; Kandadai AS; Belovodskiy A; Hena M; Vuong W; Lamer T; Young HS; Vederas JC; Tyrrell DL; Lemieux MJ; Nieman JA RSC Med Chem; 2021 Oct; 12(10):1722-1730. PubMed ID: 34778773 [TBL] [Abstract][Full Text] [Related]
15. Discovery of SARS-CoV-2 3CL Wang Y; Xu B; Ma S; Wang H; Shang L; Zhu C; Ye S Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216507 [TBL] [Abstract][Full Text] [Related]
16. Structural Basis for the Inhibition of Coronaviral Main Proteases by a Benzothiazole-Based Inhibitor. Hu X; Lin C; Xu Q; Zhou X; Zeng P; McCormick PJ; Jiang H; Li J; Zhang J Viruses; 2022 Sep; 14(9):. PubMed ID: 36146880 [TBL] [Abstract][Full Text] [Related]
17. Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332. Li J; Lin C; Zhou X; Zhong F; Zeng P; Yang Y; Zhang Y; Yu B; Fan X; McCormick PJ; Fu R; Fu Y; Jiang H; Zhang J J Virol; 2022 Apr; 96(8):e0201321. PubMed ID: 35389231 [TBL] [Abstract][Full Text] [Related]
18. Structure-Based Discovery and Structural Basis of a Novel Broad-Spectrum Natural Product against the Main Protease of Coronavirus. Zhang Y; Gao H; Hu X; Wang Q; Zhong F; Zhou X; Lin C; Yang Y; Wei J; Du W; Huang H; Zhou H; He W; Zhang H; Zhang Y; McCormick PJ; Fu J; Wang D; Fu Y; Lu X; Zhang T; Duan J; Qin B; Jiang H; Luo J; Zhang Y; Chen Q; Luo Q; Cheng L; Zhang Z; Zhang J; Li J J Virol; 2022 Jan; 96(1):e0125321. PubMed ID: 34586857 [TBL] [Abstract][Full Text] [Related]
19. Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses. Wang R; Zhai G; Zhu G; Wang M; Gong X; Zhang W; Ge G; Chen H; Chen L Bioorg Chem; 2023 Jan; 130():106264. PubMed ID: 36395603 [TBL] [Abstract][Full Text] [Related]